Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$53.4M Sell
762,777
-315,417
-29% -$16.3M 0.01% 670
2026
Q1
$54.8M Sell
1,078,194
-46,508
-4% -$2.17M 0.01% 604
2025
Q4
$33.2M Buy
1,124,702
+22,533
+2% +$612K 0.01% 848
2025
Q3
$28.5M Buy
1,102,169
+163,719
+17% +$4.57M 0.01% 919
2025
Q2
$25.9M Buy
938,450
+250,254
+36% +$6.59M 0.01% 939
2025
Q1
$19.5M Buy
688,196
+16,017
+2% +$568K 0.01% 1145
2024
Q4
$27.9M Sell
672,179
-9,998
-1% -$478K 0.01% 965
2024
Q3
$45.6M Sell
682,177
-63,923
-9% -$5.87M 0.01% 708
2024
Q2
$88.6M Sell
746,100
-60,194
-7% -$7.62M 0.03% 439
2024
Q1
$85.9M Sell
806,294
-114,355
-12% -$11.5M 0.03% 458
2023
Q4
$91.6M Sell
920,649
-38,413
-4% -$3.23M 0.03% 421
2023
Q3
$99.1M Sell
959,062
-10,352
-1% -$1.15M 0.03% 371
2023
Q2
$118M Sell
969,414
-48,081
-5% -$6.41M 0.04% 340
2023
Q1
$156M Sell
1,017,495
-11,978
-1% -$1.98M 0.06% 278
2022
Q4
$185M Buy
1,029,473
+93,423
+10% +$15.3M 0.07% 249
2022
Q3
$111M Sell
936,050
-61,815
-6% -$9.38M 0.04% 351
2022
Q2
$143M Sell
997,865
-69,932
-7% -$10M 0.06% 302
2022
Q1
$187M Sell
1,067,797
-12,767
-1% -$2.15M 0.06% 277
2021
Q4
$274M Sell
1,080,564
-191,840
-15% -$56.1M 0.08% 219
2021
Q3
$490M Sell
1,272,404
-207,313
-14% -$76.5M 0.15% 133
2021
Q2
$348M Buy
1,479,717
+298,009
+25% +$53.3M 0.1% 185
2021
Q1
$155M Sell
1,181,708
-165,428
-12% -$24M 0.05% 336
2020
Q4
$141M Buy
1,347,136
+577,249
+75% +$58.4M 0.05% 350
2020
Q3
$54.5M Sell
769,887
-299,121
-28% -$20.9M 0.02% 551
2020
Q2
$68.6M Buy
1,069,008
+256,011
+31% +$14M 0.03% 473
2020
Q1
$24.3M Buy
812,997
+89,937
+12% +$2.07M 0.01% 796
2019
Q4
$13.8M Sell
723,060
-14,651
-2% -$260K 0.01% 1395
2019
Q3
$11.7M Buy
737,711
+643,967
+687% +$9.51M ﹤0.01% 1463
2019
Q2
$1.37M Buy
+93,744
New +$2.01M ﹤0.01% 2611

Other funds holding MRNA

Nuveen's MRNA Position: Q2 2026 in Review

Nuveen reduced its Moderna (MRNA) stake by 29% in Q2 2026, selling an estimated $16.3M and leaving 762,777 shares worth $53.4M. The position accounts for 0.01% of the portfolio, ranked #670.

Nuveen first reported a position in MRNA in Q2 2019 and has held it in 29 quarters since. The position peaked at $490M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Nuveen held 762,777 shares of Moderna worth $53.4M as of Q2 2026.
  • Nuveen sold 315,417 Moderna shares in Q2 2026, an estimated $16.3M.
  • Moderna made up 0.01% of Nuveen's portfolio in Q2 2026, its #670 holding.
  • Nuveen first reported a position in Moderna in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Moderna position peaked at $490M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.